At New Pathways Clinic, we believe in empowering patients with easy access to relevant research that help guides our protocols and philosophies. We understand that because most people have not heard of ketamine infusions as a treatment for psychiatric conditions, that they may want to research it in depth themselves.
We are happy to provide a comprehensive list of links to relevant studies from some of the most important academic institutions and journals in the United States and the world. We will keep this list updated, as research on ketamine is growing at an exciting pace due to its amazing results.
Our meta-analysis suggests that single administrations of ketamine are efficacious in the rapid treatment of unipolar and bipolar depression.
“Indeed, ketamine’s remarkable rapid, robust, and sustained antidepressant effects are considered to be ‘arguably the most important discovery in half a century’ for depression research” (Harvard Medical School) (Yale School of Medicine)
“Our meta-analysis suggests that single administrations of ketamine are efficacious in the rapid treatment of unipolar and bipolar depression.” (Psychological Medicine)
“Ketamine has a robust and rapid effect on depression, which was seen immediately after the administration of ketamine and sustained at the end of 1 month.” (Central Institute of Psychiatry)
“The findings reported herein support the rapid and cumulative effects of single and repeated ketamine infusions on suicidal thoughts in individuals with TRD [Treatment Resistant Depression], even for those with high pre-treatment SI [Suicidal Ideation] severity.” (Royal Institute of Mental Health Research)
“A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression” (Journal of Affective Disorders)
Ketamine-mediated synaptic plasticity changes appear to occur within a matter of hours after ketamine administration
“Though convergence onto a specific brain area is elusive in depression, ketamine affects different areas of the brain in various ways, which may contribute to overall mood improvements.” (Harvard Medical School)
“Blockade of NMDA receptors by ketamine increases the number and function of synapses” (Yale School of Medicine)
“Ketamine-mediated synaptic plasticity changes appear to occur within a matter of hours after ketamine administration” (Mt. Sinai Hospital)
“A single subanesthetic dose infusion of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to have rapid and potent antidepressant effects in treatment-resistant Major Depressive Disorder and Bipolar Disorder Depression” (National Institute of Mental Health)
“This study provides the first replication of the ability of ketamine to normalize depression-related prefrontal dysconnectivity” (Yale School of Medicine)
Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam
“Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam” (Mount Sinai Hospital)
“Ketamine, an NMDA receptor antagonist, has recently received attention as a possible novel pharmacologic agent for PTSD given the mounting evidence of its rapid antidepressant effects in mood disorders and its robust effect on neuroplasticity” (Yale School of Medicine)
“The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population” (VA Office of Research and Development)
Participants receiving ketamine first showed significant rapid reduction in obsessions during the infusion that persisted until 1-week post-infusion compared with participants receiving placebo first
“Patients reported marked improvements in functionality and in their personal lives. Maintenance ketamine may be a therapeutic alternative for patients with treatment refractory Generalized and Social Anxiety Disorder” (Health Research Council of New Zealand)
“Participants receiving ketamine first showed significant rapid reduction in obsessions during the infusion that persisted until 1-week post-infusion compared with participants receiving placebo first” (Columbia University)
“Ketamine’s antidepressant and anti-anxiety effects are presumed to occur through activating synaptic plasticity by increasing brain-derived neurotrophic factor translation and secretion” (Maryland School of Medicine)
… This observation suggests that IV ketamine could be considered a treatment alternative for adults with Bipolar Disorder”
“A study of patients with anxious and non-anxious bipolar depression found that both anxious and non-anxious patients with bipolar depression had significant antidepressant responses to ketamine” (National Institute of Mental Health)
“Our preliminary results suggest that IV ketamine is effective in rapidly treating anxiety irritability and suicidal ideation in adults with treatment-resistant mood disorders. This observation suggests that IV ketamine could be considered a treatment alternative for adults with Bipolar Disorder” (Bipolar Disorders Journal)
These results suggest that ketamine may facilitate abstinence across multiple substances of abuse [Alcohol, Cocaine and Opioids] and warrants broader investigation in addiction treatment.
“We found that ketamine, as compared to the control, significantly decreased cocaine self-administration by 67% relative to baseline at greater than 24 h post-infusion, the most robust reduction observed to date in human cocaine users” (Columbia University)
“These results suggest that ketamine may facilitate abstinence across multiple substances of abuse [Alcohol, Cocaine and Opioids] and warrants broader investigation in addiction treatment.” (Medical University of South Carolina)
17 patients with migraine headache, significant improvements in pain were observed compared with placebo for acute pain (<1 hour) and for at least 15 days in 12 subjects following administration of subcutaneous ketamine
“17 patients with migraine headache, significant improvements in pain were observed compared with placebo for acute pain (<1 hour) and for at least 15 days in 12 subjects following administration of subcutaneous ketamine” (International Journal of Clinical Pharmacology Research)
“The simplest and most elegant explanation proposed for ketamine’s chronic pain–relieving properties is that it ‘resets the CNS,’ in essence reversing the deleterious effects of central sensitization by virtue of its NMDA-receptor antagonistic effects” (Journal of Chronic and Interventional Pain)
“IV ketamine was safely administered in the hospital setting to patients with refractory chronic migraine. Treatment was associated with short term improvement in pain severity in 6 of 6 patients with refractory chronic migraine. (Journal of Headache and Pain)
Nora Finnegan has 10 years of experience treating psychiatric conditions with Ketamine infusions from her time with the Cleveland Clinic. With a 70% success rate in significant reduction of depression and other symptoms, Ketamine infusions provide new hope for relief for those suffering from oppressive symptoms.
Do medications feel like they are merely treating surface level symptoms?
Have pills and counseling left you feeling like no treatment works for you?
Schedule a free consultation with the experienced team at New Pathways Clinic and see if Ketamine treatments could help you.